Loading...
XNAS
PALI
Market cap3mUSD
Jul 11, Last price  
0.75USD
1D
-3.46%
1Q
8.03%
IPO
-99.99%
Name

Palisade Bio Inc

Chart & Performance

D1W1MN
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
106.55%
Rev. gr., 5y
-0.78%
Revenues
0k
-100.00%
265,759306,05700733,438390,625407,708110,00018,83310,41716,246260,000260,00015,39413,52000250,0000
Net income
-14m
L+17.38%
-3,147,487-6,174,121-11,830,798-10,364,363-18,387,300-12,518,527-10,121,517-19,831,862-22,628,744-20,903,901-21,074,611-15,665,983-4,924,617-8,351,651-10,570,000-27,271,000-12,799,000-12,300,000-14,438,000
CFO
-12m
L+9.52%
-3,334,927-4,001,368-6,860,039-5,144,820-9,981,244-8,096,696-8,477,700-10,591,617-11,706,688-18,931,666-15,616,108-13,416,162-7,692,419-7,255,680-4,768,000-14,773,000-13,360,000-11,133,000-12,193,000
Earnings
Aug 11, 2025

Profile

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor that is intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress resulting from reduced blood flow to the intestine, infections, or due to surgery. The company was founded in 2005 and is headquartered in Carlsbad, California.
URL
https://palisadebio.com/
IPO date
Dec 20, 2006
Employees
12
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
250
 
Cost of revenue
14,859
13,095
15,478
Unusual Expense (Income)
NOPBT
(14,859)
(12,845)
(15,478)
NOPBT Margin
Operating Taxes
(1,461)
Tax Rate
NOPAT
(14,859)
(12,845)
(14,017)
Net income
(14,438)
17.38%
(12,300)
-3.90%
(12,799)
-53.07%
Dividends
Dividend yield
Proceeds from repurchase of equity
8,446
9,419
14,401
BB yield
Debt
Debt current
90
279
193
Long-term debt
90
301
527
Deferred revenue
Other long-term liabilities
152
63
61
Net debt
(9,641)
(11,852)
(11,689)
Cash flow
Cash from operating activities
(12,193)
(11,133)
(13,360)
CAPEX
(4)
(10)
Cash from investing activities
(4)
(10)
Cash from financing activities
9,582
11,186
15,258
FCF
(14,738)
(12,743)
(14,215)
Balance
Cash
9,821
12,432
12,383
Long term investments
26
Excess cash
9,821
12,420
12,409
Stockholders' equity
(135,915)
(121,411)
(109,158)
Invested Capital
143,649
133,156
122,102
ROIC
ROCE
EV
Common stock shares outstanding
1,416
456
59
Price
Market cap
EV
EBITDA
(14,856)
(12,841)
(15,475)
EV/EBITDA
Interest
12
15
13
Interest/NOPBT